Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

IMIDIA

Financiado

Improving beta-cell function and identification of diagnostic biomarkers for tre...

Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development... ver más

30/09/2015

SANOFIAVENTIS DEUT...

27M€

Presupuesto del proyecto: 27M€

Líder del proyecto

SANOFIAVENTIS DEUTSCHLAND GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 18 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2015-09-30

0% 100%

18 Participantes

SANOFIAVENTIS DEUTSCHLAND GM...

Lider

INSERM

N.D. | Participante

UPD

N.D. | Participante

UNIL

N.D. | Participante

Proyectos interesantes

DAMOC Diabetes Approach by Multi Organ on a Chip 1M€ Cerrado

DIRECT DIabetes REsearCh on patient sTratification 46M€ Cerrado

PID2021-122284NA-I00 BASES GENETICAS DE LA MASA DE CELULA BETA 109K€ Cerrado

PTQ-09-02-01241 Descubrimiento y desarrollo de medicamentos antidiabeticos m... 56K€ Cerrado

PTQ-09-02-01227 Descubrimiento y desarrollo de medicamentos antidiabéticos m... 70K€ Cerrado

T2D-EOMICS High throughtput electrophysiological measurements coupled w... 207K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 67 meses Fecha Inicio: 2010-02-01
Fecha Fin: 2015-09-30

Líder del proyecto

SANOFIAVENTIS DEUTSCHLAND GMBH

TRL 4-5

Presupuesto del proyecto 27M€

Descripción del proyecto An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demise in diabetes, the production of new beta-cells from progenitors,or the replication and preserved function of mature beta-cells. Here,we propose an integrated approach to generate and exploit newcellular and animal models, and to develop novel investigative tools and biomarkers to gain new knowledge on the mechanisms of beta-cell function and demise in diabetes, to improve diabetes diagnostic and to identify novel therapeutic targets for drug development. To achieve this ambitious goal,we have established a consortium of leading European experts from universities and SMEs in the fields of beta-cell diabetes research,gene transfer technology, metabolom ics, biomedical imaging, bioinformatics and systemsmodeling. We propose a work plan composed of 5 scientific work packages structured to provide high levels of interaction within the network and with EFPIA partners.A management and administration work package will permit an efficient cooperation betweenuniversities, SMEs and industrial partners to ensure that the particular interests andneeds of pharmaceutical industry research are addressed.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores